enoxaparin + prednisone

Enoxaparin + prednisone is a combination therapy involving enoxaparin, a low molecular weight heparin anticoagulant, and prednisone, a synthetic glucocorticoid corticosteroid. This combination is most notably used in reproductive medicine as part of the "Bondi protocol," an empirical immune therapy regimen for women with repeated in vitro fertilization (IVF) failure and evidence of immune dysfunction[2]. Enoxaparin acts by inhibiting clotting factors to prevent blood clot formation, while prednisone suppresses immune responses by binding to the glucocorticoid receptor and altering gene expression to reduce inflammation[4][8]. The Bondi protocol typically involves starting both drugs at the beginning of an IVF transfer cycle, with prednisolone (the active metabolite of prednisone) dosed up to 20 mg daily and enoxaparin at 20 mg daily until 12–16 weeks gestation[2]. The rationale for this combination is based on their potential synergistic effects on modulating immune activity and improving uterine receptivity; however, benefits remain debated in clinical studies.

Other names

Bondi protocol